{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-009776","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.985526+00:00","generated_at":"2026-06-06T11:09:16.278114+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Intellia reports NTLA-2002 Phase 1 data: 95% reduction in HAE attacks; 9/10 attack-free","bullets":["Single dose of NTLA-2002 led to 95% mean reduction in monthly HAE attack rate across all 10 patients.","Nine of 10 patients remained completely attack-free following the 16-week primary observation period.","All 6 patients who discontinued long-term prophylaxis reported no attacks since stopping.","NTLA-2002 well-tolerated; most common adverse events were mild infusion reactions and fatigue.","Global pivotal Phase 3 study planned for H2 2024 subject to regulatory feedback."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-009776","json":"https://secwatch.observer/filing/0000950170-24-009776.json","markdown":"https://secwatch.observer/filing/0000950170-24-009776.md","text":"https://secwatch.observer/filing/0000950170-24-009776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024009776/0000950170-24-009776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024009776/ntla-20240131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T11:09:16.278114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}